THE NEW POSSIBLE
November 14 – 15, 2018 • Harvard Medical School, Boston, MA
Speakers for the 14th Annual Personalized Medicine Conference provide head shots and biographical descriptions on a rolling basis.
Amy P. Abernethy, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer
Amy P. Abernethy, M.D., Ph.D., is the Chief Medical Officer and Chief Scientific Officer at Flatiron Health, a healthcare technology and services company focused on accelerating cancer research and improving patient care. She is a hematologist/oncologist and palliative medicine physician, and internationally-recognized cancer clinical researcher with more than 400 publications.
Dr. Abernethy is an appointee to the National Academy of Medicine’s (formerly the Institute of Medicine) National Cancer Policy Forum, on the Executive Board for the Personalized Medicine Coalition, and Past President of the American Academy of Hospice & Palliative Medicine. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine, and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. She is also on the Board of Directors of athenahealth, Inc. and was featured on TEDMED in 2013.
Edward Abrahams, Ph.D.
Personalized Medicine Coalition
Edward Abrahams, Ph.D., is the President of PMC. Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.
Previously, Dr. Abrahams was the Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.
The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has taught history and public policy at Brown University and the University of Pennsylvania.
Antonio L. Andreu, M.D., Ph.D.
European Infrastructure for Translational Medicine
Toni is an M.D., Ph.D. who specialized in genetics and genomics of rare diseases. He has been working in the field of neuromuscular disorders from the translational perspective of the pipeline, from basic science to the development of cell and animal models and clinical research.
After working at Columbia University in New York on mitochondrial disorders from 1998 to 2001, he moved to Barcelona to create the Neuromuscular Lab at the Vall d’Hebron Research Institute where he became Director of the Neurosciences Research Program.
He has also been extremely active in the field of policy-making and held positions as the Director of the Spanish National Institute of Health Carlos III, creating the national program for personalized medicine. He has also been the CEO of the Bellvitge Hospital, one of the most important University hospitals in Spain, as well as the Director General for Research and Innovation at the Catalan Ministry of Health.
Toni is now the Scientific Director at EATRIS, the European Advanced Infrastructure for Translational Research.
Steven D. Averbuch, M.D.
Vice President, Head of Precision Medicine
Dr. Averbuch is Vice President and Head, Precision Medicine within the Translational Medicine Division of R&D at Bristol-Myers Squibb. In this role, he leads integrated biomarker and pharmacodiagnostic activities across the BMS R&D portfolio.
Dr. Averbuch joined Bristol-Myers Squibb in 2006 and has led the Pharmacodiagnostics Center of Excellence since 2008. Other previous roles include: leading the strategy, business development agreements and execution of external clinical collaborations for the company’s immuno-oncology pipeline; executive sponsor and oversight for translational research activities for all late development and marketed oncology compounds; leader of corporate-wide strategic initiatives for Translational and Targeted Medicine; co-leader of the oncology early strategy team, which included responsibility for the execution of Phase 2 Oncology programs. Dr. Averbuch has made significant contributions to business development and has participated in multiple successful licensing and acquisition deals.
He previously held positions at Merck Research Laboratories, AstraZeneca, and Mount Sinai School of Medicine. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland.
Dr. Averbuch has authored over 60 peer reviewed publications and book chapters and is a co-author on one patent. He is currently on the Personalized Medicine Coalition Board of Directors, the Steering Committee of the National Biomarker Development Alliance, the Advisory Board for the University of Kansas Institute for Advancing Medical Innovation, and he is a member of the American Society of Clinical Oncology and the American Association for Cancer Research having served on multiple committees for both organizations. Dr. Averbuch is the 2014 recipient of the University of Illinois College of Medicine Distinguished Alumnus Award.
Aris Baras, M.D., M.B.A.
Vice President; Head, Regeneron Genetics Center
Regeneron Pharmaceuticals, Inc.
Dr. Baras serves as Vice President, Regeneron Pharmaceuticals and Head of the Regeneron Genetics Center (RGC), one of the largest human genetics programs in the world, spanning large-scale sequencing, informatics, and translational sciences using human genetics to advance and guide the development of Regeneron’s pipeline of important new medicines. He has established and leads several foundational genomics collaborations, such as with the Geisinger Health System to sequence at least 250,000 participants and with the UK Biobank to sequence 500,000 participants.
The RGC has produced many high impact discoveries identifying new drug targets (such as HSD17B13 in chronic liver diseases), validating existing development programs (Regeneron’s evinacumab program targeting ANGPTL3, REGN3500 targeting IL33, and many more), and contributing important new gene discoveries and precision medicine strategies. The RGC has sequenced more than 300,000 individuals to date, collaborating with more than 60 institutions around the world, and plans to sequence the genomes of millions of participants across its studies.
Previously, Dr. Baras held roles and responsibilities at Regeneron across R & D and business development. Prior to Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody-based therapeutics, cancer research and nanotechnology applications in drug development. Dr. Baras received his bachelor’s of science, M.D. and M.B.A. all from Duke University.
Cynthia A. Bens
Senior Vice President, Public Policy
Personalized Medicine Coalition
Cynthia A. Bens, Senior Vice President, Public Policy at PMC, leads the Coalition’s policy development and government relations efforts and serves as its primary liaison with the U.S. Congress and federal regulators. In collaboration with PMC’s Senior Vice President, Science Policy, Bens is responsible for implementing research, regulatory and reimbursement policy strategies that promote the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.
Before joining PMC, Bens was the Vice President of Public Policy at the Alliance for Aging Research. Bens guided the Alliance’s federal policy work, represented the organization in multiple national coalitions and directed all aspects of coalitions led by the Alliance. She spent more than a decade at the Alliance advancing policies to expedite the development of interventions for neurological diseases and physical frailty; to remove access barriers for cardiovascular disease treatments; and to enhance the quality of care for older adults living with multiple chronic conditions.
Jesse A. Berlin, Sc.D.
Vice President and Global Head of Epidemiology
Johnson & Johnson
Dr. Berlin received his doctorate in biostatistics from the Harvard School of Public Health in 1988. After spending 15 years as a faculty member at the University of Pennsylvania, in the Center for Clinical Epidemiology and Biostatistics, Jesse left Penn to join Janssen Research & Development in Biostatistics. He now serves as Vice President and Global Head of Epidemiology across Johnson & Johnson, responsible for pharmaceuticals, devices and consumer products. He has coauthored over 270 peer-reviewed publications in a variety of clinical and methodological areas, including papers on the study of meta-analytic methods for both randomized trials and epidemiology. He served on an Institute of Medicine Committee that developed recommendations for the use of systematic reviews in clinical effectiveness research, and served as Chair of the Scientific Advisory Committee to IMEDS (Innovation in Medical Evidence Development and Surveillance), part of the Reagan-Udall Foundation.
Dr. Berlin co-chairs the Scientific Oversight Committee (with Greg Pappas from FDA) for MDEpiNet, a public-private partnership which is working toward developing methods and data sources for the evaluation of medical devices. Dr. Berlin served as an editorial team member of working group X for CIOMS (The Council for International Organizations of Medical Sciences), which has published guidelines for meta-analysis of drug safety data in the regulatory context. He was elected as a fellow of the American Statistical Association in 2004. In 2013, Dr. Berlin received the Lagakos Distinguished Alumni Award from the Department of Biostatistics at the Harvard School of Public Health.
Vence L. Bonham, Jr., J.D.
Senior Advisor, Director on Genomics and Health Disparities
National Human Genome Research Institute
Vence Bonham received his bachelor of arts from James Madison College at Michigan State University and his juris doctor degree from the Moritz College of Law at the Ohio State University. Mr. Bonham was a tenured faculty member at Michigan State University in the College of Human Medicine and adjunct professor in the Michigan State University College of Law.
Since 2003, Mr. Bonham has served as an investigator in the National Human Genome Research Institute (NHGRI) within the Division of Intramural Research’s Social and Behavioral Research Branch. He leads the Health Disparities Genomics Unit, which conducts research that evaluates approaches to integrating new genomic knowledge and precision medicine into clinical settings without exacerbating inequities in healthcare delivery. His research focuses primarily on the social influences of new genomic knowledge, particularly in communities of color. He studies how genomics influences the use of the constructs of race and ethnicity in biomedical research and clinical care and the role of genomics in health inequities.
Mr. Bonham also serves as the senior advisor to the director of the National Human Genome Research Institute on genomics and health disparities.
Kristine Bordenave, M.D., F.A.C.P.
Corporate Medical Director
Kristine Bordenave M.D., F.A.C.P., is a Corporate Medical Director overseeing Humana’s National Medicare/Medicaid Clinical Review Expertise Team. Board certified in internal medicine, she is driven to ensure efficient high-quality resources to support the health of present and future generations. She has a particular interest in integration/collaboration opportunities supporting sustainable maximization of scope and/or scale while improving clinical and financial outcomes. She is a member of several organizations and has multiple publications/presentations related to chronic disease, systems redesign and population genetics.
Alex J. Carlisle, Ph.D.
Chairman, Chief Executive Officer
National Alliance Against Disparities in Patient Health
Dr. Alex Carlisle holds a doctorate in biochemistry and molecular biology from Howard University and has spent the past 17 years developing and applying translational and clinical research approaches in the areas of molecular oncology and neuroscience. Dr. Carlisle received his post-doctoral training at the U.S. National Institutes of Health, where he served at the National Cancer Institute as a leading member of the Cancer Genome Anatomy Project, and at the National Institute for Neurological Disorders and Stroke.
Dr. Carlisle went on to Fox Chase Cancer Center and later joined the Children’s Hospital of Philadelphia. Dr. Carlisle then moved to Inova Fairfax Hospital, serving as the Department of Neuroscience’s first Principal Investigator for the Inova-George Mason University Neuroscience Translational Research Laboratory. At Inova, he served as director of the Laboratory of Neuro-Oncology where he directed research programs in neuroblastoma and traumatic brain injury. He continues to serve as an Affiliate Professor of Molecular Neuroscience at George Mason University’s Krasnow Institute.
Donna R. Cryer, J.D.
President, Chief Executive Officer
Global Liver Institute
Donna R. Cryer, J.D., has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as President and CEO of the Global Liver Institute, the innovation and collaboration platform for the liver community. Ms. Cryer most recently served as Chair, President and CEO of the American Liver Foundation, the largest and oldest national nonprofit organization serving liver disease patients and their families. She was the first patient to lead the organization in its 36-year history.
For eight years, Ms. Cryer has led CryerHealth, a health care consulting firm providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations and emerging technology firms on patient engagement in health information technology, drug discovery and clinical decision-making.
William S. Dalton, Ph.D., M.D.
Founder, Executive Chairman
Dr. William (Bill) S. Dalton is Founder and Executive Chair of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to joining Moffitt, Dr. Dalton was the Dean of the University of Arizona College of Medicine. His research interests include development of information systems to allow aggregation, organization, and sharing of patient data in real time to enhance discovery and delivery of evidenced-based precision medicine.
While at Moffitt, he participated in the development of the “Total Cancer Care Protocol” designed to follow patients throughout their lifetime with patients donating their clinical data, tissue, and molecular data to support precision medicine. In 2014, the Moffitt Cancer Center partnered with the James Cancer Center at the Ohio State University to form ORIEN, a cancer center alliance of eighteen cancer centers dedicated to data sharing and collaborative research. For his leadership in the area of personalized medicine, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and computer/information networking.
In 2013, Dr. Dalton was elected into the National Academy of Inventors. He serves on numerous not for profit boards, including the National Board of the Leukemia and Lymphoma Society; he is the past-Chair of the Personalized Medicine Coalition and is the current Chair of the Institute of Human and Machine Cognition Board. He is also the past-President of the Association of American Cancer Institutes. He has served on several NCI related boards including the Board of Scientific Advisors.
Ora Dar, Ph.D.
Senior Expert, Medical Sciences, consultant to the Israel Innovation Authority
Israel Innovation Authority
Dr. Ora Dar has over 28 years of scientific, technological and operational experience, including 13 years (2005-2018) of senior management experience as the head of the Life Sciences sector at Israel Innovation Authority, and currently as a leader of National Infrastructure Platforms for Biotech R&D.
Dr. Dar initiated and implemented tools and new incentive platforms for defining and implementing the support of R&D in life sciences companies and for enhancing networking between academia and industry. Her leadership led to an annual financial funding of companies and academic research groups at a total of $60-70 million. Currently, she is among the leaders of the newly launched Israeli National Genomic and Personal Medicine Initiative, which includes the establishment of a national research-oriented Genomic-Clinical Database of 100,000 volunteers. Prior to joining the Israel Innovation Authority, Dr. Dar spent 16 years in academic research, experienced working in industry, and was a venture capital consultant for more than 25 years.
Dr. Dar is a medical sciences graduate of the Hebrew University, Jerusalem, and holds a Ph.D. from St. Mary’s Hospital Medical School, Imperial College of Science, Technology and Medicine, University of London, U.K.
Senior Vice President, Head of Product Development and Head of Research & Development
Michael Doherty joined Foundation Medicine in January 2017 as Head of Product Development and has served as Head of Research & Development since January 2018. Prior to joining the company, Mr. Doherty was Head of Regulatory Affairs at Roche Pharmaceuticals and Genentech for a period of 14 years from 2002 to 2016, overseeing the approvals of products in the field of oncology, immunology, hematology and bone disease. Prior to Roche Pharmaceuticals and Genentech, he worked in regulatory affairs at pharmaceutical companies based in the U.K., France, Switzerland and the U.S. Doherty serves as Regulatory Strategy Adviser to VisionGate, a clinical stage cancer diagnostics and therapeutics company and as a member of the board of Monarch BioNetworks.
Mr. Doherty has a BSc in Biochemistry from the University of Reading,. a fellowship of the Institute of Medical Sciences, and a Diploma in Management Studies from the University of Portsmouth, in the U.K.
Gregory Dorn, M.D.
Greg Dorn is a Senior Vice President of Hearst and the President and Group Head of Hearst Health, overseeing Hearst’s health care businesses in the U.S. and globally, including FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MedHOK, Hearst Health Ventures, and the Hearst Health Innovation Lab. He also serves as a Director of M2Gen.
For more than two decades, Dorn has been focused on raising the standard of excellence for patient care across the health care spectrum, through clinically rigorous guidance delivered by efficient, scalable technology. He is the co-inventor of two patented health care software technologies that continue to be used in health systems across the U.S.
Dorn has held a variety of leadership positions across Hearst, including Chief Operating Officer of Zynx Health and President of FDB. In 2013 he was appointed a Vice President of Hearst to lead its growing portfolio of health care companies, and became President of Hearst Health in 2014. Each year in the U.S., care guidance from Hearst Health reaches 85 percent of discharged patients, 205 million insured individuals, 70 million home health visits and 3.2 billion dispensed prescriptions.
Dorn received his medical doctorate from the Columbia University College of Physicians and Surgeons and his bachelor’s degree from the Columbia University School of Engineering. He performed his clinical training at UCLA, where he also obtained his master’s degree in health services management.
Stephen L. Eck, M.D., Ph.D.
Chief Medical Officer; Board Chair
Immatics US Inc.; Personalized Medicine Coalition
Stephen L. Eck M.D., Ph.D., is a Hematologist/Oncologist with extensive experience in the development of pharmaceuticals and their companion diagnostics. He is currently Chief Medical Officer of Immatics (Houston, TX), which develops novel cancer immunotherapeutics. He is Chairman of the Board of the Personalized Medicine Coalition (Washington D.C.). He also serves on the Board of Directors of Luminex Corporation (Austin, TX) and Cirulogene (Birmingham, AL), which develop and market medical diagnostics. He also serves on the Board of Trustees of the Keck Graduate Institute (Claremont, CA) and on the Board of Directors of the Central Pennsylvania Clinic (Belleville, PA), which serves patients with rare genetic disorders.
Previously, Dr. Eck has held a variety of industry leadership positions at Aravive Biologics, Astellas Pharma, Lilly and Pfizer and served on the faculty of the University of Michigan School of Medicine and the University of Pennsylvania School of Medicine. He holds a B.S. degree from Kalamazoo College, a M.D. degree from the University of Mississippi and a Ph.D. from Harvard University.
Adolph P. Falcón, M.P.P.
Executive Vice President
National Alliance for Hispanic Health
As the Executive Vice President of the National Alliance for Hispanic Health, Adolph Falcon provides leadership and management for the Alliance’s program portfolio and development efforts. He also oversees the science and policy portfolio of the Alliance, including serving as Director of the Alliance’s Healthy Americas Institute at the University of Southern California Keck School of Medicine.
A nationally recognized expert on Hispanic health policy, he played a leading role in the landmark Disadvantaged Minority Health Improvement Act of 1990 and most recently has been active in the Children’s Health Insurance Program Reauthorization Act, Sugar-Sweetened Beverages Tax Act, Personal Care Products Safety Act, and regulatory efforts to improve the quality of health care.
Joseph V. Ferrara
Chief Executive Officer
Boston Healthcare Associates
Mr. Ferrara has over 20 years of experience in life sciences consulting, working with biopharmaceutical, medical device, diagnostics, and health care IT clients in market and business development strategy. He leads the global consulting team with practice areas in reimbursement and pricing, health economics, market analysis, and business development strategy. Mr. Ferrara has extensive experience in the development of novel business approaches designed to capture evidence-based value for innovation health care technologies. Mr. Ferrara writes and speaks extensively on the subject of the value of medical technology innovation, with particular focus on pharmacogenomics, specialty pharmaceuticals, and novel therapeutic devices.
Prior to his consulting role, Mr. Ferrara led a joint venture between Boston Healthcare and a non-profit research organization focused on a global electronic medical record network for the purposes of clinical trials and health outcomes research.
Mr. Ferrara completed undergraduate studies at the University of Cincinnati and received a master’s degree from Harvard University.
Tom Fowler, Ph.D.
Deputy Chief Scientist
Dr. Tom Fowler is Genomics England’s Director of Public Health and Deputy Chief Scientist. In this capacity Tom works to support the science stream around rare diseases, infectious diseases and cancer. In particular, he has led the rare disease pilot phase of the 100,000 Genomes Project. He also coordinates the Project’s infectious disease strand, which is led primarily by Public Health England.
Following a Ph.D. in Behavioural Genetics in 2003, his career began as a Specialist Registrar in Public Health, working in the NHS. He has worked in both commissioning and specialised commissioning as well as roles such as regional epidemiologist and health protection consultant.
As a locum Public Health consultant at the Chief Medical Officer’s Private Office in 2011-2013, Tom was editor-in-chief of the ‘Annual State of the Public’s Health’ (Vol. I), a comprehensive review of health data for England. During this time, Tom worked with the Chief Medical Officer of England on thought leadership around public health, including wellbeing and antimicrobial resistance. Tom was a member of the Public Health Genomics European Network (PHGEN) meeting that led to the Declaration of Rome 2012 summary of the European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies.
Birgit Funke, Ph.D.
VP Clinical Affairs
Dr. Funke received her Ph.D. in molecular genetics from the University of Würzburg, Germany and trained as a postdoctoral fellow at the Albert Einstein College of Medicine in New York where she identified the gene for 22q11 deletion syndrome. She subsequently completed a fellowship in Clinical Molecular Genetics at Harvard Medical School and has dedicated her career to personalized genetic medicine since then.
She served as the director of Clinical Research and Development at the Laboratory for Molecular Medicine (LMM) and was among the first worldwide to implement clinical next generation sequencing (NGS). She also has a extensive experience in clinical diagnostic testing for inherited cardiovascular disorders and is co-chairing the cardiovascular domain working group of the Clinical Genome Resource (ClinGen) whose mission is to harmonize and centralize knowledge resources for genomic medicine.
Today, Dr. Funke is Vice President of Clinical Affairs at Veritas Genetics and part time Associate Professor of Pathology at Harvard Medical School. Her long term goal is to use genomic testing for disease prevention.
Sean George, Ph.D.
Chief Executive Officer
Sean is chief executive officer of Invitae, whose mission is to bring genetic information into mainstream medicine. Prior to his CEO position, he served as Invitae’s president and chief operating officer. Sean was a co-founder and CEO of Locus Development, an early stage genetic analysis startup that later merged with Invitae.
Prior to co-founding Locus, he served as COO at Navigenics, an early leader in personalized medicine. Previously, he has also served as SVP of Marketing and SVP, Life Science Business at Affymetrix as well as VP, Labeling and Detection Business at Invitrogen. In the past, he has also worked at McKinsey & Co. and Molecular Probes. Dr. George holds a B.S. in Molecular Genetics from UCLA, an M.S. in Molecular Biology from UC Santa Barbara, and a Ph.D. in Molecular Genetics from UC Santa Cruz.
Luba Greenwood, J.D.
Strategic Business Development and Corporate Ventures
Verily, an Alphabet Company
Luba brings to Verily pharmaceutical, biotechnology, and digital health industry experience and expertise in building and advising innovative technology companies and providing strategic counsel to global corporations. Previously, Luba has served as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub for the Diagnostics Division. Luba is on the Board of MassBio and IRX Therapeutics, and serves as Advisor to Dana-Farber Cancer Institute, as part of its Business Development Council. She is also a Lecturer at Boston University Law School and School of Management where she has taught courses in life sciences, business law, innovation, and entrepreneurship since 2014.
Luba’s career has spanned leadership roles in venture investing, business development, Mergers & Acquisitions, law, and operations, previously serving as Venture Partner at Colt Ventures, leading BD and Strategy for Pronutria, a Flagship Ventures company, and serving as Senior Mergers & Acquisitions Counsel at Pfizer Inc. Luba began her career practicing law at a leading national law firm, Wilmer Cutler Pickering Hale and Dorr, where she represented clients in securities, IP, regulatory, corporate, and litigation matters.
Luba is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology. Luba served as non-profit board member of Longwood Symphony Orchestra, executive coach for MassNextGen, co-chair of MassBio’s Entrepreneur’s University, and mentor and judge for MassCONNECT, MIT 100K Entrepreneurship Competition, and MassChallenge.
Richard Hamermesh, D.B.A.
Harvard Business School Kraft Precision Medicine Accelerator
Richard Hamermesh is a Senior Fellow at the Harvard Business School, where he was formerly the MBA Class of 1961 Professor of Management Practice. Currently, Richard is the Faculty Co-Chair of the Kraft Precision Medicine Accelerator. Richard created and teaches the second-year MBA elective, Building Life Science Businesses. Previously, he was the course head for the required first-year course, The Entrepreneurial Manager.
From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School.
Richard is also an active investor and entrepreneur, having participated as a principal, director and investor in the founding and early stages of more than 20 organizations. He was the founding president of the Newton Schools Foundation and served on the editorial board of the Harvard Business Review.
Richard is the author or co-author of five books, including New Business Ventures and The Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published more than 100 case studies and numerous articles, including his recent publications “What Precision Medicine Can Learn from the NFL” and “One Obstacle to Curing Cancer: Patient Data isn’t Shared.”
Chairman, Chief Executive Officer, Co-founder
Colin Hill is a leading voice in machine learning in health care and precision medicine. He co-founded GNS Healthcare in 2000 and has since served as Chairman & CEO. Colin sits on the board of Biotelemetry Inc. (NASDAQ: BEAT), the leading mobile health information company, and PPD, a leading global contract research organization. Colin was a founding member of the Board of Directors of AesRx, (acquired by Baxter in 2014). In 2004, Colin was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35.
Peter Juhn, M.D., M.P.H.
Vice President, Global Head of Value-Based Partnerships
Dr. Peter Juhn is Vice President and Global Head of Value-based Partnerships at Amgen. He is responsible for implementing partnerships with payers, care delivery organizations and other key healthcare stakeholders that can lead to more clinical improvement opportunities for patients with serious and debilitating illnesses and result in greater overall value for the healthcare system.
Most recently he was Vice President for Integrated Care Services in the Global Diabetes Division at Sanofi, where he was responsible for creating new patient service platforms and their attendant new business models. He led the business planning efforts for the Sanofi joint venture in diabetes with Verily (aka Google Life Sciences).
Prior to Sanofi, he was at Medco Health Solutions (at the time, the largest PBM with 65 million enrollees) as President of the Therapeutic Resource Centers division, leading a team of over 1000 pharmacists providing medication management support to Medco’s members, and then as Chief Medical Officer of Medco International where he led the delivery of medication support programs for clients in the UK, Germany, Sweden and the Netherlands. Prior to that, he was Vice President of Evidence and Regulatory Policy at Johnson & Johnson, where he was responsible for evidence-based medicine at the J&J Corporate level. He was also Vice President of Health Improvement Resources, at WellPoint Health Networks, where he managed the disease management programs for all its operating units, including Blue Cross of California. He also held senior positions at Kaiser Permanente, including founding head of the Care Management Institute, which is Kaiser’s corporate disease management and clinical policy division, and President and CEO of CareTouch, Inc., an e-health start-up venture.
Julie Khani, M.P.A.
American Clinical Laboratory Association
Julie Khani became President of the American Clinical Laboratory Association (ACLA) in 2017. She joined ACLA in July 2013 as Senior Vice President and was named Executive Vice President in 2016.
Khani leads ACLA’s efforts to advance public policies that promote innovation and protect and enhance patient access to life-improving and life-saving diagnostics. ACLA members represent the diversity of the clinical laboratory industry and include national, regional, specialty, hospital, ESRD, anatomic pathology, skilled nursing facility and academic medical center laboratories.
Ms. Khani is recognized as an effective leader, consensus builder and advocate. Prior to joining ACLA, she served in senior roles at the National Association of Chain Drug Stores (NACDS). She was instrumental in the inclusion of pharmacy access standards in Medicare Part D, establishing incentives for TRICARE beneficiaries to obtain immunizations at retail pharmacies and the implementation of the Affordable Care Act provisions on Medicaid reimbursement for generic drugs.
Previously, Khani served as Legislative Manager at Ford Motor Company, where she was responsible for health and labor issues and the company’s political action committee. Ms. Khani was also Associate Director, Government Relations, at Planned Parenthood Pennsylvania Advocates, where she managed several successful statewide campaigns on health and welfare issues. She holds a bachelor of arts from New York University and a master of public administration from George Washington University.
David King, J.D.
David King, J.D., is the Chairman and CEO of Laboratory Corporation of America Holdings (LabCorp), one of the world’s largest networks of clinical laboratories. Prior to joining LabCorp in 2001, Mr. King worked for many years as the company’s outside counsel as a partner with Hogan & Hartson LLP (now Hogan Lovells) in Baltimore, Maryland.
Mr. King sits on the board of Cardinal Health, Inc., a Fortune 100 health care company. He also chairs the board of the American Clinical Laboratory Association and serves on the board of the Seattle Science Foundation.
Emily Kramer-Golinkoff, M.B.E.
Co-Founder, Patient Advocate
Emily Kramer-Golinkoff is Co-Founder of Emily’s Entourage, a 501(c)3 that accelerates research for new treatments and a cure for Cystic Fibrosis. She is also an internationally recognized patient advocate and speaker.
Named a “Champion of Change” for President Obama’s Precision Medicine Initiative, Emily’s Entourage has awarded over $3.4 million in research grants since 2011, leading worldwide efforts to fast-track research and drug development on nonsense mutations of CF. The organization has been featured in CNN.com, Time.com, People.com and more.
Emily has a master’s degree in bioethics and certification in clinical ethics mediation from the University of Pennsylvania, where she also completed her undergraduate degree.
President and Chief Executive Officer
Marc LePage is President and CEO of Genome Canada. Before assuming this role in January 2016, he served as President and CEO of Génome Québec since December 2011, where he led a major increase in research activity and enhanced focus on the development of genomic applications within priority sectors within the province.
He brings a wealth of experience in the innovation sector and venture capital, in addition to a broad network of international contacts.He is an expert in international partnerships and previously served as Special Advisor, Climate Change and Energy for the Embassy of Canada in Washington, D.C. and worked as Consul General at the Canadian Consulate in San Francisco/Silicon Valley.
Marc LePage was also one of the pioneers behind the founding of Genome Canada in 2000. During his tenure as Executive Vice-President of Corporate Development, he made a significant contribution to the development of genomics in Canada.
From 1994 to 2000, he worked as Director of Business Development for the Medical Research Council, where he was in charge of building international partnerships with the pharmaceutical industry, venture capital and foundations.
Nick Leschly, M.B.A.
Chief Executive Officer
Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc.
Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO), Synlogic and Proclara Biosciences.
Founder, Publisher; Board Member
Genome magazine; Personalized Medicine Coalition
Susan brings 30 years of journalistic experience to her role as Publisher for Genome magazine — the first consumer magazine exclusively devoted to personalized medicine and genomics.
With over 300,000 copies distributed across the US each quarter, Genome covers the personalized medicine stories of today and the breakthroughs of tomorrow, so that patients have the information they need to get the targeted treatments they deserve. Prior to its launch, she spent 10 years as the publisher of CURE — a magazine for cancer patients, survivors and caregivers. During her tenure at CURE, she also served as Vice President of Patient Engagement for McKesson Specialty Health.
In 2016, Susan was honored by Folio as one of the “Top Women in Media” for her entrepreneurial efforts in magazine publishing and media. She has over 20 years of experience delivering first-class sales and management strategies to leading and start-up media and health care organizations, and is especially skilled at creating collaborative partnerships that result in highly respected educational offerings for patients and health care providers.
GreyBird Ventures, LLC
After earning a graduate degree from the Harvard/MIT Health Sciences and Technology program, Tom joined Siemens where he ran the global MRI business. He has also served as the CEO of the global medical operations of Carl Zeiss, the CEO of Analogic Corporation, and Chairman and CEO of LightLab Imaging, a start-up he helped to establish and sell. Tom re-joined Siemens in 2002 serving as a member of the Global Operating Board and Division CEO of Siemens Healthcare with 26,000 employees in over 130 countries. In 2013, Tom started GreyBird Ventures, an investment firm focused on technologies for precision medicine diagnosis. Tom is a speaker on healthcare technology at conferences around the world and serves as director or chairman on the boards of five medical technology companies.
Cynthia Casson Morton, Ph.D.
William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology and Professor of Pathology; Kenneth J. Ryan, M.D. Distinguished Chair in Obstetrics and Gynecology
Harvard Medical School; Brigham and Women’s Hospital
Cynthia Casson Morton received her Bachelor’s of Science degree from the College of William and Mary in Virginia and her Ph.D. in Human Genetics from the Medical College of Virginia in Richmond. Dr. Morton is certified by the American Board of Medical Genetics in Ph.D. Medical Genetics, Clinical Cytogenetics and Clinical Molecular Genetics. Her research interests are in molecular cytogenetics, hereditary deafness, genetics of uterine leiomyomata and human developmental disorders. She has published over 300 original articles.
Dr. Morton served as Director of the Biomedical Research Institute (BRI) at Brigham and Women’s Hospital (BWH). As Director of Cytogenetics at BWH, Dr. Morton has implemented the use of next-generation sequencing to provide nucleotide resolution of balanced chromosomal rearrangements detected in the prenatal setting. Her laboratory has been a major site for training laboratory geneticists in clinical cytogenetics.
Dr. Morton served as President of the American Society of Human Genetics in 2014. She was a member of the Board of Directors of the Society and completed a six year tenure as Editor of its journal, The American Journal of Human Genetics. She is currently Co-Editor of Human Genetics. Dr. Morton also is a past member of the Board of Directors of the American Board of Medical Genetics where she served as Secretary, Treasurer and Chair of the Accreditation Committee. She was the Chair of the Molecular Genetic Pathology Policy and Exam Committees of the American Board of Medical Genetics and the American Board of Pathology.
Dr. Morton served as Member and Chair of the Board of Scientific Counselors of the National Institute of Deafness and Other Communication Disorders (NIDCD), and as Member and Chair of the Board of Regents of the National Library of Medicine. She is currently a member of the Council of Scientific Trustees of the Hearing Health Foundation and has recently been appointed to the Advisory Council of the NIDCD. Dr. Morton is a Fellow of the American Association for the Advancement of Science.
Elizabeth Nabel, M.D.
Brigham and Women's Hospital
Betsy Nabel has served as president of Harvard-affiliated Brigham Health–an academic health care system which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization–since 2010. A cardiologist and distinguished biomedical researcher, Nabel is Professor of Medicine at Harvard Medical School.
Nabel brings a unique perspective to health care based on her experience as a physician, research scientist, academic medicine leader, and wellness advocate. At Brigham Health, Nabel is leading development of a new model of academic medicine devoted to maintaining and restoring health through leadership in scientific discovery, education, and compassionate care. Initiatives include a new translational research and clinical facility, leading-edge care redesign, and a $1.5 billion campaign to advance life-giving breakthroughs.
Nabel has a long record of advocacy for health and broadening access to care. As director of the National Heart, Lung, and Blood Institute from 2005-2009, Nabel leveraged the $3 billion research portfolio to establish pioneering scientific programs in genomics, stem cells, and translational research. One of her signature advocacy efforts was the Red Dress Heart Truth campaign, which raises heart awareness in women through unprecedented industry partnerships.
An accomplished physician-scientist, Nabel’s work on the molecular genetics of cardiovascular diseases has produced 17 patents and more than 250 scientific publications. Nabel’s scientific contributions in cardiovascular gene transfer have developed molecular and cellular techniques, delineated that the pathophysiology of atherosclerosis and clarified the processes of cell division and growth of vascular smooth muscle cells in blood vessels. Her studies on Hutchinson-Gilford Progeria Syndrome have characterized the vascular smooth muscle cell defect leading to premature heart attack and stroke.
Daniel P. O’Day, M.B.A.
Chief Executive Officer
Daniel O’Day is the Chief Executive Officer of Roche Pharmaceuticals and a member of the Roche Corporate Executive Committee.
Daniel has been in his current role since 2012 and previously served as Chief Executive Officer of Roche Diagnostics. His global career spans three decades of diverse leadership roles across North America, Asia Pacific and Europe.
After joining Roche Pharmaceuticals in 1987, Daniel held various roles in the U.S. before moving to Roche headquarters in Switzerland in 1998. During his time there he held leadership roles in Global Marketing and Lifecycle Management. In 2001, Daniel’s career took him to Tokyo, where he was Head of Corporate Planning for Roche Pharma in Japan and later to Denmark as General Manager.
Daniel became President of Roche Molecular Diagnostics in California in 2006 and subsequently returned to Roche headquarters to lead the Diagnostics Division.
Daniel holds a Bachelor of Science in Biology from Georgetown University in Washington D.C., and an M.B.A. from Columbia University in New York.
Global Marketing Director, Health and Life Sciences Group; Stage IV Prostate Cancer Patient
Bryce Olson is the Global Marketing Director for Intel’s Health and Life Sciences group. One of the areas he focuses on is bringing technology and science together in the exciting area of genomics and precision medicine with a powerful message on how this saves lives. Genomic sequencing and precision medicine gave him a life he didn’t think he’d get to live.
Bryce is inspired by connecting the advances in life sciences into clinical settings and helping patients understand these new opportunities. He is a sought after keynote speaker both locally and nationally, and his story has been covered by both local and national media. Bryce also started FACTS (‘Fighting Advanced Cancer Through Songs’), a movement that uses the power of music to build awareness for a new way to fight cancer and bring molecular testing and precision medicine to other advanced cancer patients. In 2017, Bryce wrote and co-produced a rock-n-roll album with proceeds going towards the FACTS movement, that brought together a variety of Portland, Oregon based musicians and singers including Jenny Conlee from the Decemberists, Martha Davis from the Motels, Pete Krebs, and Michelle DeCourcy – all four who are also cancer survivors.
Michael Pellini, M.D., M.B.A.
Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI) from May 2011 until he transitioned to Chairman in February 2017.
He currently serves as a member of the Board of Directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies, Octave Health, Vineti, the Personalized Medicine Coalition, and the Mission Hospital Foundation, in addition to his Board Chair position with Foundation Medicine. As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. Dr. Pellini is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health).
Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.
Cary Pfeffer, M.D.
Third Rock Ventures
Cary Pfeffer joined Third Rock Ventures at its inception in 2007 and has more than 20 years of business development and transaction experience, along with a broad array of biotech product development experience. Cary leads our partner development efforts, including building and maintaining strong relationships to work with large biotech and pharmaceutical companies. He has played an instrumental role in a number of innovative alliances and collaborative company building efforts across our portfolio, including an industry-leading global strategic collaboration between Agios and Celgene in the field of cancer metabolism. Cary supports and advises on business development efforts across our portfolio and has also assumed active leadership roles in our portfolio companies, functioning as chief executive officer and chief business officer through the first 12-18 months after launch.
Before joining Third Rock, Cary founded The Pfeffer Group, a boutique consulting firm that provided business development and strategy advisory services, completing multiple transactions for leading biotechnology and life sciences companies. Prior to that, Cary spent more than a decade at Biogen where he held a variety of senior and executive level U.S. and global management roles focused on business and market development, product development and commercial operations.
Chairman of the Board, Chief Executive Officer and President
Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. Kim has served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer.
Kim currently serves on the boards of the California Life Sciences Association (CLSA), the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), and MyoKardia, Inc. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Advisor to the Healthcare Businesswomen’s Association (HBA). Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area from 2006-2012 by the San Francisco Business Times. She was also named Woman of the Year in 2008 by the Women Health Care Executives. Kim holds a Bachelor of Arts degree in Business from Michigan State University.
Daryl Pritchard, Ph.D.
Senior Vice President, Science Policy
Personalized Medicine Coalition
Daryl Pritchard, Ph.D., is the Senior Vice President of Science Policy at the PMC, where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory and payment policies.
Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council. Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the Biotechnology Innovation Organization (BIO).
Dr. Pritchard received his Ph.D. and master’s degree in genetics from the George Washington University, and completed a post-doctoral research fellowship at the Children’s National Medical Center. He was awarded the first American Society of Human Genetics/NHGRI Fellowship in Genetics and Public Policy, where he worked as a health legislative assistant in the House of Representatives.
Scott D. Ramsey, M.D., Ph.D.
Full Member; Director
Fred Hutchinson Cancer Research Center; Hutchinson Institute for Cancer Outcomes Research
Dr. Ramsey is a general internist and health economist. He is a Full Member in the Cancer Prevention Program, Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, where he directs Hutchinson Institute for Cancer Outcomes Research, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. In addition, Dr. Ramsey is a Professor in the Schools of Medicine and Pharmacy at the University of Washington.
Trained in Medicine and economics, Dr. Ramsey’s research focuses on economic evaluations in cancer. He has published widely on patterns of care, costs, and cost-effectiveness of treatments for lung, colorectal, and prostate cancer. His research portfolio and interests include: large scale SEER-Medicare/Cancer Registry data linkages, patient reported outcomes, economic modeling of health care interventions, cost-effectiveness analysis, quality of life assessment, patterns of care, health care utilization, economic burden of disease for patients and society, pragmatic trial design, early technology assessment, and stakeholder engagement.
Dr. Ramsey is co-Chair of the Outcomes and Comparative Effectiveness Committee of the Southwest Oncology Group, past President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the IOM Cancer Policy Forum.
William A. Sahlman, Ph.D.
Baker Foundation Professor
Harvard Business School
William Sahlman is a Baker Foundation Professor of Business Administration at Harvard Business School. Mr. Sahlman received an A.B. degree in Economics from Princeton University (1972), an M.B.A. from Harvard University (1975), and a Ph.D. in Business Economics (1982), also from Harvard. He joined the Harvard Business School faculty in 1980.
His research focuses on the investment and financing decisions made in entrepreneurial ventures at all stages in their development. Mr. Sahlman has written numerous articles and two textbooks on topics including entrepreneurial management, venture capital, private equity, deal structuring, incentives, commercializing science, impact investing, and the role of entrepreneurship in the global economy.
In 1985, Mr. Sahlman introduced a new second-year elective course called Entrepreneurial Finance. Over 8,000 students have taken that course since it was first offered. In 2000, Mr. Sahlman helped design and introduce The Entrepreneurial Manager, a required course in the First Year MBA curriculum. Mr. Sahlman has published over 200 cases and notes for classroom use.
From 2007 to 2016, Mr. Sahlman was Senior Associate Dean for External Relations. He is co-chair of the Rock Center for Entrepreneurship. He was co-chair of the Entrepreneurial Management Unit from 1999 to 2002. From 1991 to 1999, he was Senior Associate Dean, Director of Publishing Activities, and chairman of the board for Harvard Business School Publishing Corporation. From 1990 to 1991, he was chairman of the Harvard University Advisory Committee on Shareholder Responsibility. From 2009 to 2015, he was chairman of the Advisory Committee for Harvard Stem Cell Science. He is a member of the board of advisors or board of directors of several private companies. In 2011, Mr. Sahlman participated in The IPO Task Force, a private group focused on regulatory reform of the initial public offering process. The Task Force published a report called: Rebuilding the IPO On-Ramp: Putting Emerging Growth Companies and the Job Market Back on the Road to Growth.
Michael Sherman, M.D., M.B.A., M.S.
Chief Medical Officer, Senior Vice President
Harvard Pilgrim Health Care
Dr. Michael Sherman serves as Chief Medical Officer and Senior Vice President for health services for Harvard Pilgrim Health Care. A pioneer in developing outcomes-based payment agreements with pharmaceutical companies, he recently signed the first value-based agreement for a gene therapy used to treat a form of blindness.
Dr. Sherman serves as chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and on the Advisory Board of the Institute for Clinical and Economic Review (ICER). He also is the current chair for AHIP’s CMO Leadership Council, and serves on the board of directors for the Personalized Medicine Coalition, and on the board of advisors for the Harvard Business School Healthcare Initiative.
Prior to joining Harvard Pilgrim, Dr. Sherman served as corporate medical director, physician strategies for Humana, and he previously held leadership positions at UnitedHealth Group, Thomson Medstat (now IBM Truven), HealthAllies, which was purchased by UnitedHealth Group in 2003, Immusol, and Da Vita.
Dr. Sherman holds a B.A. in Anthropology and Natural Sciences and an M.S. in Biomedical Anthropology from the University of Pennsylvania. He received his M.D. from Yale and M.B.A. from the Harvard Business School. Dr. Sherman is a diplomate of the American Board of Anesthesiology and American Board of Medical Management. In 2009, he was named a fellow of the American College of Physician Executives, and he currently serves on the faculty of the Department of Population Medicine at Harvard Medical School.
Ellen V. Sigal, Ph.D.
Friends of Cancer Research
Ellen V. Sigal, Ph.D., is Chairperson and Founder of Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, DC, that drives collaboration among partners from every health care sector to power advances in science, policy and regulation that speed life-saving treatments to patients. During the past 20 years, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible.
Dr. Sigal is Chair of the Board of Directors of the Reagan-Udall Foundation, a partnership designed to modernize medical product development, accelerate innovation and enhance product safety in collaboration with the U.S. Food and Drug Administration. She also serves on the board of the Foundation for the National Institutes of Health, where she chairs its Public Private Partnerships Committee.
Lauren Silvis, J.D.
Chief of Staff, Immediate Office of the Commissioner
Lauren Silvis serves as the Chief of Staff to FDA Commissioner Scott Gottlieb, M.D. In this capacity, she provides advice and counsel to the Commissioner and acts as the Commissioner’s direct liaison to other agencies and organizations on key initiatives. She also works closely with the agency’s individual product centers to support their implementation of agency policy and commitments. She provides strategic direction to senior leadership to advance agency priorities.
Ms. Silvis has deep expertise in all aspects of the Federal Food, Drug and Cosmetic Act and the oversight of FDA-regulated products. She has significant experience in regulatory and compliance issues, including clinical trials, premarket review and approval, product safety and promotion, import and export, and current good manufacturing practice.
Before being appointed Chief of Staff, Ms. Silvis served as Deputy Center Director for Policy in FDA’s Center for Devices and Radiological Health. In this role, she led the development and implementation of all medical device policies, regulations, and guidance, and oversaw the Center’s communication and education functions. She regularly advised on regulatory, programmatic and legislative issues affecting medical devices and represented the Center on cross-cutting Agency policy issues.
Prior to joining FDA in 2015, Ms. Silvis was a partner practicing food and drug regulatory law at a large international law firm. She graduated cum laude from Duke University and earned her law degree cum laude from Georgetown University Law Center, after which she served as a law clerk to the Honorable James L. Ryan, U.S. Court of Appeals for the Sixth Circuit.
Ariel D. Stern, Ph.D.
Assistant Professor, Technology and Operations Management Unit
Harvard Business School
Ariel Dora Stern is an Assistant Professor of Business Administration and Hellman Faculty Fellow in the Technology and Operations Management Unit at Harvard Business School. She teaches the Technology and Operations Management course in the MBA required curriculum.
Ariel’s research focuses on the management of innovation in health care, with a focus on the medical device and pharmaceutical industries. Her projects seek to understand the drivers of innovation among firms and the determinants of how medical technologies are adopted and used in practice. Ariel is particularly interested in the intersection of the regulation, firm strategy, and economics of health care. She also researches the digital transformation of medical technology and health care delivery, investigating the policy and managerial questions raised by the growth of “digital health.” Her research has been cited by Bloomberg, The New York Times, and National Public Radio.
Mark P. Stevenson, M.B.A.
Executive Vice President, Chief Operating Officer
Thermo Fisher Scientific
Mark Stevenson has been Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific since August 2017, with responsibility for all of Thermo Fisher’s life sciences-related businesses as well as the company’s innovation and digital strategy. He joined the company as Executive Vice President and President, Life Sciences Solutions, through the acquisition of Life Technologies in 2014.
Mark previously served as President and Chief Operating Officer of Life Technologies, and President and Chief Operating Officer of Applied Biosystems prior to its merger with Invitrogen Corporation in 2008.
Mark received his MBA from Henley Management School in the U.K. and his bachelor’s degree in chemistry from the University of Reading, also in the U.K.
A. Keith Stewart, M.B., CH.B.
Carlson and Nelson Endowed Director, Center for Individualized Medicine
Keith Stewart, M.B., CH.B., M.B.A., is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine at Mayo Clinic. He currently serves as the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine and is recognized as the Vasek and Anna Maria Polak Professor of Cancer Research. Dr. Stewart’s current responsibilities at Mayo Clinic relate to the application of genomics to human health across the spectrum of discovery, translation and application to clinical practice.
Dr. Stewart has served in several leadership roles across both research and clinical practice at Mayo Clinic, including as dean for research in Arizona, and as a member of the Arizona Executive Operations Team and Clinical Practice Committees. He has served on multiple boards for both non-profit and commercial organizations, including currently as a Non-Executive Board member with Genomics England, Oncospire Inc. and OneOme Inc.
His own research interest is in the genomics and biology of myeloma and he has led numerous clinical trials of new drugs for this blood cancer. Dr. Stewart has over 25 years of sustained national funding for a laboratory research program and has authored over 300 journal articles and other written publications. He has served as an associate editor of Blood and ASH Clinical News.
Gregg Talbert, Ph.D.
Global Head of Digital and Personalized Health Care Partnering
Gregg Talbert, Ph.D., is the Global Head of Digital and Personalized Health Care Partnering at Roche. In this role, he is responsible for developing and implementing a business development strategy that supports the execution of Roche’s personalized health care strategy.
Prior to serving in this capacity, Dr. Talbert served as Roche’s Global Head of Strategic Partnering. He has also served in a variety of strategy and business development positions at Eli Lilly and Company.
Executive Vice President
Asian & Pacific Islander American Health Forum
Ed is the Executive Vice President at APIAHF. In this role, he shepherds the organization’s strategic thinking, long-term strategy planning, evaluation, innovation, and leadership development efforts. With nearly two decades of service as a nonprofit manager leader and as a Certified Professional Coach, Ed seeks to help individuals and organizations lean into their internal purpose, values, and vision.
Before joining APIAHF in 2002, Ed was involved in HIV prevention and capacity building. As a former food blogger, he continues to seek out new ways to continue to pursue his passions for cooking meals that feed one’s stomach and soul as well as capturing images that spark wanderlust through digital photography.
Meg Tirrell joined CNBC in April 2014 as a General Assignment Reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC‘s Business Day programming, contributes to CNBC.com and is based at the network’s global headquarters in Englewood Cliffs, NJ.
Tirrell has covered development of new drugs for Alzheimer’s, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind “compassionate use” of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on the development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek. She holds a master’s degree in journalism from Northwestern University and a bachelor’s degree in English and music from Wellesley College.
Sean Tunis, M.D., M.Sc.
Founder and Chief Executive Officer
Center for Medical Technology Policy
As the President and Chief Executive Officer of the Center for Medical Technology Policy (CMTP), Sean Tunis, MD, MSc, engages multiple experts, stakeholders, and decision-makers in working toward consensus on methods for CER, with the goal of providing guidance for product developers and researchers as they design CER and pragmatic clinical studies. He has nearly 20 years of professional experience with health technology assessment, comparative effectiveness, health services research, and clinical research.
Prior to founding CMTP, Tunis served as the director of the Office of Clinical Standards and Quality and the Chief Medical Officer at the Centers for Medicare and Medicaid Services, where he led the development and implementation of the concept of coverage with evidence development, which was applied to support the design and implementation of several large pragmatic clinical trials and registries. For each study, he established multi-stakeholder working groups to set study objectives and decide on elements of study protocol, data collection strategy, and other aspects of these studies.
Liisa-Maria Voipio-Pulkki, M.D., Ph.D.
Director General, Chief Medical Officer, Ministry of Social Affairs and Health
Dr. Liisa-Maria Voipio-Pulkki is currently serving as the Director General of Strategic Affairs and Chief Medical Officer of the Finnish Ministry of Social Affairs and Health. She joined the Ministry in 2010 as the Director of the Health Care Group. Previously she was employed as the Senior Medical Adviser of the Finnish Association of Local and Regional Authorities in 2004-2009, Chief of Emergency and Acute Care of the Helsinki University Hospital District in 2000-2004 and as a specialist and Adjunct Professor of Medicine in the University of Turku, Finland.
She earned her M.D. degree in 1973 (University of Helsinki) and her Ph.D. in 1986 (University of Turku). She was a guest researcher at the NHLBI in 1989-1990. She is a specialist in internal medicine and cardiology and has published over 100 original papers in cardiovascular medicine. Her current interests include medical and health technology innovation policies, implementation of precision medicine, sustainability of health systems, and medical ethics.
In 2017 she was elected to chair the Steering Committee of the European Observatory on Health Systems and Policies, a WHO hosted partnership, based in Brussels. She resides in Helsinki and is actively involved in the preparations for the Finnish EU Presidency in 2019.
Darrell M. West, Ph.D.
Vice President of Governance Studies, Director of the Center for Technology Innovation, Douglas Dillon Chair in Governance Studies
The Brookings Institution
Darrell M. West is the Vice President of Governance Studies and Director of the Center for Technology Innovation at The Brookings Institution. He holds the Douglas Dillon Chair in Governance Studies.
Previously, he was the John Hazen White Professor of Political Science and Public Policy and Director of the Taubman Center for Public Policy at Brown University. His current research focuses on technology policy, artificial intelligence and data analytics.
West is the author of 23 books, including The Future of Work: Robots, Al, and Automation (Brookings, 2018). His books have been translated into Chinese, Japanese, and Korean, and he has delivered nearly 150 lectures in a dozen different countries, including China, Japan, Russia, Taiwan, Mexico, Brazil, Germany, Netherlands, Portugal, Turkey, Bahrain, and the United States, and has been quoted in leading newspapers, radio stations, and national television networks around the world.
He is the winner of the American Political Science Association’s Don K. Price award for best book on technology (for Digital Government) and the American Political Science Association’s Doris Graber award for best book on political communications (for Cross Talk).